Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jul 11, 2026·v1

Polycystic Ovary Syndrome

PCOS is a common endocrine disorder with reproductive, metabolic, and psychological manifestations; management is phenotype-driven and includes lifestyle, pharmacotherapy (COCP, letrozole, metformin, GLP-1 RAs), and bariatric surgery for severe obesity, with long-term surveillance for diabetes, CVD, NAFLD, and mental health.

High Evidence271 references·2,657 words·11 min read·v1
PCOSpolycystic ovary syndromehyperandrogenismanovulationinsulin resistancehirsutisminfertilityendocrinologygynecologymetabolic syndrome

Quick Reference

RxDrug of choiceLetrozole 2.5-7.5 mg daily for ovulation induction; combined oral contraceptives (low-dose EE 20-35 mcg) for cycle control and hyperandrogenism.
AltAlternativesClomiphene 50-150 mg/day for ovulation induction; metformin 1500-2000 mg/day for metabolic dysfunction; GLP-1 RAs (liraglutide, semaglutide) for weight loss; spironolactone 50-100 mg BID for hirsutism.
⊘AvoidValproate (increases PCOS risk); high-dose estrogen COCPs in women with cardiovascular risk factors; non-dihydropyridine CCBs not relevant but avoid if heart failure present.
DxTest of choiceTransvaginal ultrasound with high-frequency probe for PCOM; 75-g OGTT for glucose tolerance; 17-OHP with ACTH stimulation to exclude NCAH.
ScKey scoreRotterdam criteria (2 of 3: hyperandrogenism, ovulatory dysfunction, PCOM); modified Ferriman-Gallwey score for hirsutism; STOP-Bang for sleep apnea screening.
→When to referEndocrinology for NCAH or complex metabolic cases; reproductive endocrinology for infertility; bariatric surgery for BMI ≥35 kg/m² after lifestyle failure; mental health for depression/anxiety.
PCOS is a chronic condition requiring multidisciplinary, phenotype-driven management with emphasis on lifestyle, appropriate pharmacotherapy for reproductive and metabolic goals, and long-term surveillance for cardiometabolic and psychiatric comorbidities.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder of reproductive-age women, affecting 5-18% worldwide and defined by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. It carries significant reproductive, metabolic, and psychological implications, with a 2.3-2.5-fold increased risk of major adverse cardiovascular events and a 3-7-fold higher risk of type 2 diabetes. The 2023 International Evidence-Based Guideline endorses the Rotterdam criteria for diagnosis, emphasizing phenotype-based stratification and shared decision-making for management.

Overview and Recommendations

Background

  • •PCOS is a common endocrine disorder affecting 5-18% of reproductive-age women, defined by the 2003 Rotterdam criteria requiring at least two of three features: hyperandrogenism (clinical or biochemical), ovulatory dysfunction, and polycystic ovarian morphology (PCOM) on ultrasound. It is the leading cause of anovulatory infertility and carries a 2.3- to 2.5-fold increased risk of major adverse cardiovascular events by age 35.
  • •The condition is characterized by a self-reinforcing triangle of neuroendocrine dysregulation (elevated LH pulse frequency due to reduced hypothalamic sensitivity to progesterone), insulin resistance (present in 50-70% of women, independent of obesity), and ovarian hyperandrogenism. Insulin acts as a co-gonadotropin, upregulating ovarian CYP17A1 and suppressing hepatic SHBG, leading to elevated free testosterone.
  • •Four phenotypes exist under Rotterdam: A (classic, hyperandrogenism + ovulatory dysfunction + PCOM, highest metabolic risk), B (hyperandrogenic anovulation without PCOM), C (ovulatory PCOS, hyperandrogenism + PCOM), and D (normoandrogenic PCOS, ovulatory dysfunction + PCOM, most controversial). The Androgen Excess Society requires hyperandrogenism for diagnosis, excluding phenotype D.
  • •The 2023 International Evidence-Based Guideline retains Rotterdam criteria and recommends using population-specific cut-offs for PCOM (follicle number per ovary ≥20, ovarian volume ≥10 mL) and modified Ferriman-Gallwey score for hirsutism. In adolescents, diagnosis requires both hyperandrogenism and irregular cycles; PCOM is not used due to poor specificity during normal puberty.
  • •PCOS is associated with significant long-term risks: 3- to 7-fold higher risk of type 2 diabetes, pooled relative risk of 3.46 for endometrial cancer (due to unopposed estrogen from anovulation), and a high prevalence of depression (37%) and anxiety (48%). The disorder also predisposes to NAFLD, obstructive sleep apnea, and adverse pregnancy outcomes including gestational diabetes and preeclampsia.

Evaluation

  • •Suspect PCOS in any reproductive-age woman presenting with oligomenorrhea (fewer than eight cycles per year), hirsutism, acne, or infertility. Ask about age of menarche, menstrual pattern, weight gain, family history of PCOS or diabetes, and symptoms of hyperandrogenism.
  • •Examine for hirsutism using the modified Ferriman-Gallwey (mFG) score; a score ≥4-6 is abnormal depending on ethnicity. Look for acne, seborrhea, acanthosis nigricans (sign of insulin resistance), and measure BMI and waist circumference (≥88 cm in Caucasian women, ≥80 cm in Asian women).
  • •Order biochemical assessment: total testosterone, free testosterone (or calculated free androgen index), SHBG, androstenedione, DHEAS. Use LC-MS/MS for accurate measurement. Also measure 17-hydroxyprogesterone (17-OHP) to exclude non-classic congenital adrenal hyperplasia (NCAH); if >6 nmol/L (≈2 ng/mL), perform an ACTH stimulation test (250 μg cosyntropin, 17-OHP at 60 min; >10 ng/mL is diagnostic for NCAH).
  • •Exclude alternative causes: thyroid dysfunction (TSH), hyperprolactinemia (prolactin), Cushing syndrome (if clinical suspicion with 24-h urine cortisol, overnight dexamethasone suppression test, or late-night salivary cortisol), and androgen-secreting tumors (if total testosterone >5 nmol/L or rapid virilization, order ovarian/adrenal imaging).
  • •Perform a 75-g oral glucose tolerance test (OGTT) at diagnosis to screen for impaired glucose tolerance or type 2 diabetes, even if fasting glucose is normal. Repeat every 1-3 years based on risk.
  • •Order transvaginal ultrasound with a high-frequency probe (≥8 MHz) to assess for PCOM: follicle number per ovary (FNPO) ≥20 and/or ovarian volume ≥10 mL in either ovary. Anti-Müllerian hormone (AMH) is a surrogate marker (proposed cutoff 3.5-5 ng/mL) but not yet a formal diagnostic criterion due to inter-assay variability.
  • •Diagnostic criteria for adults: presence of at least two of three features (hyperandrogenism, irregular cycles, PCOM/AMH) after excluding other causes. For adolescents: both hyperandrogenism and irregular cycles required; PCOM excluded.
  • •Classify into phenotype: A (HA+OD+PCOM), B (HA+OD), C (HA+PCOM), D (OD+PCOM). This stratifies metabolic and reproductive risk and guides management intensity.
  • •Consider referral to endocrinology if NCAH is confirmed, or to reproductive endocrinology for infertility evaluation. Also consider sleep studies if obstructive sleep apnea is suspected (STOP-Bang score).

Management

  • •Initiate lifestyle intervention as the foundation: structured dietary modification, physical activity (aerobic exercise best for BMI reduction, combined aerobic+resistance for insulin resistance, mind-body exercise for glucose), and behavioral strategies. Aim for 5-10% weight loss, which reduces insulin resistance, lowers androgens, and restores ovulation in 30-50% of women.
  • •For menstrual regularity and suppression of hyperandrogenism (hirsutism, acne), prescribe combined oral contraceptives (COCP) as first-line: low-dose ethinyl estradiol (20-35 mcg) with a progestin (e.g., drospirenone, cyproterone acetate). Use for women not seeking pregnancy and without contraindications. Fourth-generation progestins offer additional antiandrogenic benefit but higher VTE risk.
  • •For metabolic dysfunction (insulin resistance, prediabetes, type 2 diabetes), use metformin 1500-2000 mg/day (start 500 mg BID, titrate to 850-1000 mg BID). Metformin improves menstrual cyclicity, reduces fasting insulin, and may improve live birth rates (OR 1.59 vs placebo) but is less effective for hirsutism. Monitor renal function and vitamin B12 annually.
  • •For ovulation induction in women desiring pregnancy, use letrozole 2.5-7.5 mg daily for 5 days starting cycle day 3-5. Letrozole is superior to clomiphene (live birth rate 27.5% vs 19.1%, NNT=12) with higher cumulative ovulation rates (61.7% vs 48.3%) and no increase in multiple pregnancy. Clomiphene 50-150 mg/day is second-line.
  • •For women with obesity (BMI ≥35 kg/m²) and PCOS, consider bariatric surgery (sleeve gastrectomy) after lifestyle failure. Surgery achieves 78% remission of PCOS vs 15% with medical therapy, and increases spontaneous ovulation 2.5-fold (BAMBINI trial). Remission is predicted by achieving final BMI <26-27.5 kg/m².
  • •For adjunctive weight loss in obese PCOS, consider GLP-1 receptor agonists (e.g., liraglutide 1.2 mg daily, semaglutide 1.0 mg weekly). They reduce BMI by ~1.4 kg/m² and improve metabolic parameters, but may cause lean mass loss (~28% of weight loss). Use off-label; monitor for gastrointestinal side effects.
  • •For IVF, use frozen-embryo transfer rather than fresh: higher live birth rate (49.3% vs 42.0%, NNT=14) and lower ovarian hyperstimulation syndrome (1.3% vs 7.1%, NNT=17). Monitor for preeclampsia (4.4% vs 1.4%, NNH=33).
  • •During pregnancy, consider metformin 500-1000 mg BID to reduce late miscarriage and preterm birth (PregMet2 trial: OR 0.50, 95% CI 0.22-1.08, pooled analysis significant). Metformin is safe during breastfeeding and does not increase congenital malformations.
  • •Monitor for endometrial hyperplasia in women with prolonged amenorrhea (>3-4 months) or abnormal uterine bleeding; perform transvaginal ultrasound or endometrial biopsy. Do not screen asymptomatic women routinely.
  • •Screen for depression and anxiety using PHQ-9 and GAD-7 at diagnosis and annually; refer to mental health services as needed. Prevalence of depression is 37%, anxiety 48%.
  • •Titrate therapy to targets: regular menstrual cycles (21-35 days), free androgen index <5, fasting glucose <100 mg/dL, HbA1c <5.7%, blood pressure <130/80 mmHg, LDL-C <130 mg/dL.
  • •For hirsutism not responding to COCP, add antiandrogens like spironolactone 50-100 mg BID (off-label; use with effective contraception due to teratogenicity). Consider eflornithine cream for facial hirsutism.
  • •Avoid valproate in women of reproductive age as it increases PCOS risk (HR 7.08 for >365 DDDs). Avoid high-dose estrogen COCPs in women with cardiovascular risk factors.
  • •Refer to bariatric surgery if BMI ≥35 kg/m² and lifestyle/metformin fail. Refer to reproductive endocrinology if ovulation induction with letrozole fails after 6 cycles.

Board Review — High Yield

  • •Rotterdam criteria, requires 2 of 3: hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology. Exclude other causes.
  • •Letrozole first-line for ovulation induction, superior to clomiphene (live birth 27.5% vs 19.1%, NNT=12).
  • •Phenotype A (hyperandrogenism + anovulation + PCOM) has highest metabolic and cardiovascular risk.
  • •Non-classic CAH must be excluded with 17-OHP; if >6 nmol/L, do ACTH stimulation test.
  • •Metformin improves menstrual cyclicity and reduces diabetes risk but does not improve hirsutism.
  • •Bariatric surgery achieves 78% remission in obese PCOS (BMI ≥35 kg/m²).
  • •Frozen embryo transfer preferred in IVF to reduce OHSS (1.3% vs 7.1%) and improve live birth.
  • •Depression and anxiety affect 37% and 48% of women with PCOS, screen routinely.
  • •GLP-1 receptor agonists are emerging for weight loss but cause lean mass loss.
  • •Premature adrenarche is a forerunner of PCOS, higher fasting insulin in affected girls.

Deep Dive — Evidence Details

References

  1. [1]

    Azziz R, Carmina E, Dewailly D et al.. “Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16940456 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature
  2. [2]

    Teede HJ, Tay CT, Laven JJE et al.. “Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” European journal of endocrinology (2023). PMID: 37580861 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  3. [3]

    Conway G, Dewailly D, Diamanti-Kandarakis E et al.. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” European journal of endocrinology (2014). PMID: 24849517 ↗

    L5GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  4. [4]

    Hu L, Ma L, Xia X et al.. “Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35554540 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  5. [5]

    Rissetti G, Piovezan JM, Premaor MO et al.. “Contrasting Bone Profiles in PCOS Are Related to BMI: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38739756 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  6. [6]

    Iliodromiti S, Kelsey TW, Anderson RA et al.. “Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23775353 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  7. [7]

    Davitadze M, Malhotra K, Khalil H et al.. “Body image concerns in women with polycystic ovary syndrome: a systematic review and meta-analysis.” European journal of endocrinology (2023). PMID: 37619990 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  8. [8]

    Ollila MM, Arffman RK, Korhonen E et al.. “Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study.” European journal of endocrinology (2023). PMID: 37436934 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  9. [9]

    Teede HJ, Tay CT, Laven JJE et al.. “Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37580314 ↗

    L1OTHERCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  10. [10]

    Hoeger KM, Dokras A, Piltonen T. “Update on PCOS: Consequences, Challenges, and Guiding Treatment.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33211867 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  11. [11]

    Vale-Fernandes E, Pignatelli D, Monteiro MP. “Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons.” European journal of endocrinology (2025). PMID: 40186490 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  12. [12]

    Kiconco S, Earnest A, Enticott J et al.. “Normative cut-offs for polycystic ovary syndrome diagnostic features in adolescents using cluster analysis.” European journal of endocrinology (2023). PMID: 37243570 ↗

    L4OTHERCited in: Definition, Classification and Axis Nomenclature
  13. [13]

    Joham AE, Norman RJ, Stener-Victorin E et al.. “Polycystic ovary syndrome.” The lancet. Diabetes & endocrinology (2022). PMID: 35934017 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  14. [14]

    Teede HJ, Khomami MB, Morman R et al.. “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” Lancet (London, England) (2026). PMID: 42119588 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  15. [15]

    Norman RJ, Dewailly D, Legro RS et al.. “Polycystic ovary syndrome.” Lancet (London, England) (2007). PMID: 17720020 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  16. [16]

    Jiang M, Wang T, Huang L. “Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42381874 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  17. [17]

    Güner Emül T, Kaplan Serin E. “The Relationship Between 2D:4D Digit Ratio and Polycystic Ovary Syndrome: A Systematic Review.” American journal of human biology : the official journal of the Human Biology Council (2026). PMID: 42249717 ↗

    L3SR_OBSCited in: Definition, Classification and Axis Nomenclature, Prognosis, Natural History and Prevention
  18. [18]

    Fernando SPW, Ramdass PVAK. “Adiponectin and Polycystic Ovary Syndrome in Adolescent Girls: A Systematic Review and Meta-Analysis.” International journal of molecular sciences (2026). PMID: 42123535 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  19. [19]

    Cao Q, Du S, Li Z et al.. “Neuropsychiatric disorders in children of mothers with polycystic ovary syndrome: a systematic review and meta-analysis.” BMC psychiatry (2026). PMID: 41935305 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  20. [20]

    Palomba S, Costanzi F, Seminara G et al.. “Is polycystic ovary syndrome associated with uterine malformations? A systematic review using Bradford Hill's causality framework.” Human reproduction open (2026). PMID: 41696680 ↗

    L3SR_OBSCited in: Definition, Classification and Axis Nomenclature
  21. [21]

    Dumont T, Peeva M, El Masri M. “Diagnosis and treatment of PCOS in adolescents: a summary of guidelines and systematic reviews for practitioners.” Best practice & research. Clinical obstetrics & gynaecology (2026). PMID: 41616460 ↗

    L5SR_OBSCited in: Definition, Classification and Axis Nomenclature
  22. [22]

    Dapas M, Dunaif A. “Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification.” Endocrine reviews (2022). PMID: 35026001 ↗

    L5OTHERCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  23. [23]

    Dumesic DA, Oberfield SE, Stener-Victorin E et al.. “Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.” Endocrine reviews (2015). PMID: 26426951 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  24. [24]

    Franik S, Le QK, Kremer JA et al.. “Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2022). PMID: 36165742 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  25. [25]

    Tang T, Lord JM, Norman RJ et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2010). PMID: 20091537 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  26. [26]

    Tang T, Lord JM, Norman RJ et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2009). PMID: 19821299 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  27. [27]

    Elkind-Hirsch KE, Chappell N, Seidemann E et al.. “Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34097062 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  28. [28]

    Jensterle Sever M, Kocjan T, Pfeifer M et al.. “Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.” European journal of endocrinology (2014). PMID: 24362411 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
  29. [29]

    Bril F, Ezeh U, Amiri M et al.. “Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37329216 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  30. [30]

    Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  31. [31]

    Escobar-Morreale HF, Roldán-Martín MB. “Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis.” Diabetes care (2016). PMID: 27208367 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  32. [32]

    Studen KB, Sebestjen M, Pfeifer M et al.. “Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.” European journal of endocrinology (2010). PMID: 21156647 ↗

    L2TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  33. [33]

    Forslund M, Wändell P, Forsberg L et al.. “GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis.” European journal of endocrinology (2026). PMID: 41701618 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  34. [34]

    Lerchbaum E, Obermayer-Pietsch B. “Vitamin D and fertility: a systematic review.” European journal of endocrinology (2012). PMID: 22275473 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  35. [35]

    Krul-Poel YH, Snackey C, Louwers Y et al.. “The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review.” European journal of endocrinology (2013). PMID: 24044903 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  36. [36]

    Gambineri A, Semple RK, Forlani G et al.. “Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin.” European journal of endocrinology (2008). PMID: 18728124 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Prognosis, Natural History and Prevention
  37. [37]

    Cena H, Chiovato L, Nappi RE. “Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32442310 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  38. [38]

    Azziz R, Amiri M, Bril F et al.. “Approach to the Patient: Hirsutism.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40200552 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  39. [39]

    Zhu T, Goodarzi MO. “Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34669940 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  40. [40]

    Goodarzi MO, Jones MR, Chen YD et al.. “First evidence of genetic association between AKT2 and polycystic ovary syndrome.” Diabetes care (2008). PMID: 18768676 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  41. [41]

    Beckman JA, Goldfine AB, Dunaif A et al.. “Endothelial function varies according to insulin resistance disease type.” Diabetes care (2007). PMID: 17261751 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  42. [42]

    Gosseaume C, Fournier T, Jéru I et al.. “Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy.” European journal of endocrinology (2023). PMID: 36806620 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  43. [43]

    Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  44. [44]

    Savas M, Kuckuck S, Boon MR et al.. “Beyond weight loss: multisystem benefits of obesity medications.” The lancet. Diabetes & endocrinology (2026). PMID: 42208956 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  45. [45]

    O'Reilly M, Gathercole L, Capper F et al.. “Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome.” Lancet (London, England) (2015). PMID: 26312838 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  46. [46]

    Stener-Victorin E, Carlsson S, Hagström H et al.. “MASLD, diabetes and PMOS across the female life stages.” Diabetologia (2026). PMID: 42249186 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  47. [47]

    Meier JJ, Nauck MA. “Incretin-based therapies: where will we be 50 years from now?” Diabetologia (2015). PMID: 25994073 ↗

    L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  48. [48]

    Sam S, Ehrmann DA. “Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.” Diabetologia (2017). PMID: 28770330 ↗

    L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  49. [49]

    Tan BK, Chen J, Digby JE et al.. “Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome.” Diabetologia (2006). PMID: 17001470 ↗

    L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  50. [50]

    Diamanti-Kandarakis E, Dunaif A. “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.” Endocrine reviews (2012). PMID: 23065822 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  51. [51]

    di Clemente N, Racine C, Pierre A et al.. “Anti-Müllerian Hormone in Female Reproduction.” Endocrine reviews (2021). PMID: 33851994 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  52. [52]

    Hsueh AJ, Kawamura K, Cheng Y et al.. “Intraovarian control of early folliculogenesis.” Endocrine reviews (2014). PMID: 25202833 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  53. [53]

    Stener-Victorin E, Padmanabhan V, Walters KA et al.. “Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.” Endocrine reviews (2020). PMID: 32310267 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
  54. [54]

    Anderson RC, Newton CL, Anderson RA et al.. “Gonadotropins and Their Analogs: Current and Potential Clinical Applications.” Endocrine reviews (2018). PMID: 29982442 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  55. [55]

    El Dib R, Gameiro OL, Ogata MS et al.. “Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.” The Cochrane database of systematic reviews (2015). PMID: 26020622 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  56. [56]

    Franik S, Eltrop SM, Kremer JA et al.. “Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2018). PMID: 29797697 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  57. [57]

    Meza N, Bracchiglione J, Escobar Liquitay CM et al.. “Liraglutide for adults living with obesity.” The Cochrane database of systematic reviews (2025). PMID: 41161684 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  58. [58]

    Beletate V, El Dib RP, Atallah AN. “Zinc supplementation for the prevention of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17253560 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  59. [59]

    Skalkidou A, Sergentanis TN, Gialamas SP et al.. “Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility.” The Cochrane database of systematic reviews (2017). PMID: 28349511 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  60. [60]

    Dziewierz A, Kulicka N, Stolarska K et al.. “Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.” Diabetes, obesity & metabolism (2026). PMID: 42297761 ↗

    L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  61. [61]

    Zhao Z. “Associations between serum persistent organic pollutants and polycystic ovary syndrome risk: a case-control study with mediation analysis.” Frontiers in public health (2026). PMID: 42338522 ↗

    L3CASE_CONTROLCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  62. [62]

    Odunvbun WO, Ukoba O, Isogun JK et al.. “A systematic review of pregnancy outcomes and management in polycystic ovary syndrome.” African journal of reproductive health (2026). PMID: 42202883 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  63. [63]

    Ji C, Zheng X, Wang Q et al.. “A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome caused by a De Novo INSR c.3328G>C mutation.” Frontiers in endocrinology (2026). PMID: 42272804 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  64. [64]

    Javed M, Suramya S, Javed H et al.. “A Review of microRNAs in the Post-transcriptional Regulation and its Clinical Manifestation in the Polycystic Ovary Syndrome.” Reproductive sciences (Thousand Oaks, Calif.) (2026). PMID: 42426428 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  65. [65]

    Juneja S, Bhati BS. “MedFusionNet: A hybrid transformer-based multimodal deep learning framework for chronic disease prediction in women's health.” Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society (2026). PMID: 42424829 ↗

    L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  66. [66]

    Hu R, Li F, Dong H et al.. “Kuntai capsule ameliorates PCOS by reversing tryptophan metabolic shift and aberrant nuclear AHR activation: a multi-omics investigation.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42398205 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  67. [67]

    Legro RS, Arslanian SA, Ehrmann DA et al.. “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24151290 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  68. [68]

    Eisenberg E, Legro RS, Diamond MP et al.. “Sleep Habits of Women With Infertility.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34180998 ↗

    L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  69. [69]

    Legro RS, Dodson WC, Kris-Etherton PM et al.. “Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26401593 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  70. [70]

    Meyer C, McGrath BP, Teede HJ. “Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.” Diabetes care (2007). PMID: 17327307 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  71. [71]

    Dietz de Loos A, Jiskoot G, Beerthuizen A et al.. “Metabolic health during a randomized controlled lifestyle intervention in women with PCOS.” European journal of endocrinology (2021). PMID: 34714771 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  72. [72]

    Amiri M, Hatoum S, Hopkins D et al.. “The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39078989 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  73. [73]

    Cooney LG, Gyorfi K, Sanneh A et al.. “Increased Prevalence of Binge Eating Disorder and Bulimia Nervosa in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39115340 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification
  74. [74]

    Pace L, Markovic D, Buyalos R et al.. “Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39106216 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  75. [75]

    Løvvik TS, Carlsen SM, Salvesen Ø et al.. “Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.” The lancet. Diabetes & endocrinology (2019). PMID: 30792154 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  76. [76]

    Legro RS, Brzyski RG, Diamond MP et al.. “Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.” The New England journal of medicine (2014). PMID: 25006718 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  77. [77]

    Ben Said W, Lempesis IG, Fernandez-Garcia S et al.. “Premature adrenarche and metabolic risk: a systematic review and meta-analysis.” European journal of endocrinology (2025). PMID: 40884153 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  78. [78]

    Neven ACH, Forslund M, Ranashinha S et al.. “Prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents across world regions: a systematic review and meta-analysis.” European journal of endocrinology (2024). PMID: 39353075 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  79. [79]

    Samarasinghe SNS, Leca B, Alabdulkader S et al.. “Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2024). PMID: 38782004 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  80. [80]

    Piltonen TT, Koskenkari N, Koivuaho E et al.. “Increased mortality in polycystic ovary syndrome- a cohort study.” European journal of endocrinology (2026). PMID: 42213411 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  81. [81]

    Kakoly NS, Earnest A, Teede HJ et al.. “The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome.” Diabetes care (2019). PMID: 30705063 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  82. [82]

    Karakas SE, Kim K, Duleba AJ. “Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome.” Diabetes care (2010). PMID: 20067969 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  83. [83]

    Palomba S, Falbo A, Russo T et al.. “The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome.” Diabetes care (2012). PMID: 22338097 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  84. [84]

    Gaberšček S, Zaletel K, Schwetz V et al.. “Mechanisms in endocrinology: thyroid and polycystic ovary syndrome.” European journal of endocrinology (2015). PMID: 25422352 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  85. [85]

    Guo S, Xia H, Yang W et al.. “Clinical efficacy of acupuncture for women with PCOS undergoing IVF/ICSI: a meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 42290862 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
  86. [86]

    Thong EP, Codner E, Laven JSE et al.. “Diabetes: a metabolic and reproductive disorder in women.” The lancet. Diabetes & endocrinology (2019). PMID: 31635966 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  87. [87]

    Schoonejans JM, Blackmore HL, Ashmore TJ et al.. “Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.” Diabetologia (2022). PMID: 36112170 ↗

    L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
  88. [88]

    Baillargeon JP, Carpentier AC. “Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects.” Diabetologia (2007). PMID: 17898989 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  89. [89]

    Barber TM, Bennett AJ, Groves CJ et al.. “Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome.” Diabetologia (2008). PMID: 18478198 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  90. [90]

    Barber TM, Bennett AJ, Groves CJ et al.. “Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS.” Diabetologia (2007). PMID: 17805508 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  91. [91]

    Fornaro M, Di Lorenzo C, Steardo L et al.. “Prevalence and outcomes of co-occurring psychiatric and endocrine, metabolic, and nutritional disorders: An atlas based on umbrella review of 254,154,533 records.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026). PMID: 42217371 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  92. [92]

    Stańczyk K, Łopacińska O, Kędzia D et al.. “Depressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42194542 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  93. [93]

    Eng PC, Phylactou M, Qayum A et al.. “Obesity-Related Hypogonadism in Women.” Endocrine reviews (2024). PMID: 37559411 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  94. [94]

    Randeva HS, Tan BK, Weickert MO et al.. “Cardiometabolic aspects of the polycystic ovary syndrome.” Endocrine reviews (2012). PMID: 22829562 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  95. [95]

    Tso LO, Costello MF, Albuquerque LET et al.. “Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 33347618 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  96. [96]

    Weiss NS, Kostova EB, Mol BWJ et al.. “Gonadotropins for ovulation induction in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2025). PMID: 40193219 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  97. [97]

    Fraison E, Kostova E, Moran LJ et al.. “Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 32794179 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  98. [98]

    Zhuang J, Wang X, Xu L et al.. “Antidepressants for polycystic ovary syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23728677 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  99. [99]

    Tang T, Lord JM, Norman RJ et al.. “WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.” The Cochrane database of systematic reviews (2009). PMID: 19588338 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  100. [100]

    Tso LO, Costello MF, Albuquerque LE et al.. “Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2014). PMID: 25406011 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  101. [101]

    Weiss NS, Kostova E, Nahuis M et al.. “Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 30648738 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  102. [102]

    Han Q, Li M, Li G et al.. “A nomogram to predict early spontaneous abortion in women with polycystic ovary syndrome: a retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42432589 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  103. [103]

    Lee SH, Lee KS, Lee JY et al.. “Impact of gestational diabetes on future diabetic retinopathy and microvascular complications: a nationwide cohort study.” BMC medicine (2026). PMID: 42399945 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
  104. [104]

    Sung J, Chang R, Chen SN et al.. “Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42248807 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  105. [105]

    Machado IFR, Tinano FR, Latronico AC et al.. “Approach to the diagnosis and treatment of polycystic ovarian syndrome in adolescent patients.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42105324 ↗

    L5OTHERCited in: Clinical Presentation
  106. [106]

    Franks S. “Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16418209 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  107. [107]

    Actkins KV, Singh K, Hucks D et al.. “Characterizing the Clinical and Genetic Spectrum of Polycystic Ovary Syndrome in Electronic Health Records.” The Journal of clinical endocrinology and metabolism (2021). PMID: 32961557 ↗

    L4OTHERCited in: Clinical Presentation
  108. [108]

    Suturina L, Lizneva D, Lazareva L et al.. “Ethnicity and the Prevalence of Polycystic Ovary Syndrome: The Eastern Siberia PCOS Epidemiology and Phenotype Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38888252 ↗

    L4OTHERCited in: Clinical Presentation
  109. [109]

    Yildiz BO, Knochenhauer ES, Azziz R. “Impact of obesity on the risk for polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17925334 ↗

    L4OTHERCited in: Clinical Presentation
  110. [110]

    Santoro N. “Update in hyper- and hypogonadotropic amenorrhea.” The Journal of clinical endocrinology and metabolism (2011). PMID: 22058375 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  111. [111]

    Broughton S, Armeni E, Chu A et al.. “The association between body image and well-being in polycystic ovary syndrome: a mixed-methods study.” European journal of endocrinology (2026). PMID: 41656064 ↗

    L4OTHERCited in: Clinical Presentation, Severity, Staging and Risk Stratification
  112. [112]

    Romero-Ruiz A, Pineda B, Ovelleiro D et al.. “Molecular diagnosis of polycystic ovary syndrome in obese and non-obese women by targeted plasma miRNA profiling.” European journal of endocrinology (2021). PMID: 34403358 ↗

    L3OTHERCited in: Clinical Presentation
  113. [113]

    Barth JH, Field HP, Yasmin E et al.. “Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots.” European journal of endocrinology (2009). PMID: 20008514 ↗

    L4OTHERCited in: Clinical Presentation
  114. [114]

    McCartney CR, Marshall JC. “CLINICAL PRACTICE. Polycystic Ovary Syndrome.” The New England journal of medicine (2016). PMID: 27406348 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  115. [115]

    Lu F, Yu H, Feng J et al.. “The impact of age on clinical features and fertility outcomes in patients with polycystic ovary syndrome: a secondary analysis based on the PCOSAct trial.” Frontiers in endocrinology (2026). PMID: 41625240 ↗

    L2RCTCited in: Clinical Presentation
  116. [116]

    Chauhan S, Muka T, Najaf SS et al.. “Effects of yoga interventions on Anti-Müllerian hormone, androgen levels, and metabolic parameters in women with polycystic ovary syndrome: a systematic review.” BMC complementary medicine and therapies (2026). PMID: 41782111 ↗

    L1SR_OBSCited in: Clinical Presentation
  117. [117]

    Ghaderzadeh M, Garavand A, Salehnasab C. “Artificial intelligence in polycystic ovary syndrome: a systematic review of diagnostic and predictive applications.” BMC medical informatics and decision making (2025). PMID: 41286838 ↗

    L3SR_OBSCited in: Clinical Presentation
  118. [118]

    Lim SS, Hutchison SK, Van Ryswyk E et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 30921477 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  119. [119]

    Moran LJ, Hutchison SK, Norman RJ et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2011). PMID: 21328294 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis, Natural History and Prevention
  120. [120]

    Moran LJ, Hutchison SK, Norman RJ et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2011). PMID: 21735412 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis, Natural History and Prevention
  121. [121]

    Ibibama JO, Madaki PD, Aliche KA et al.. “Environmental Toxicants and Polycystic Ovary Syndrome: Implications for a Metabolic-Ovarian Framework (PMOS) - A Systematic Review.” Biological trace element research (2026). PMID: 42426543 ↗

    L2SR_OBSCited in: Clinical Presentation
  122. [122]

    Atinga A, Bashiru HA, Solomon AO et al.. “Depression and anxiety among women with polycystic ovarian syndrome in low- and middle-income countries: a systematic review and meta-analysis.” Frontiers in global women's health (2025). PMID: 41378340 ↗

    L2SR_OBSCited in: Clinical Presentation
  123. [123]

    . “[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 41820035 ↗

    L1GUIDELINECited in: Clinical Presentation, Severity, Staging and Risk Stratification, History and Evolution of Treatment
  124. [124]

    Al Wattar BH, Fisher M, Bevington L et al.. “Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33839790 ↗

    L5GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  125. [125]

    Jensterle M, Kovac J, Vovk A et al.. “Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40341357 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  126. [126]

    Hutchison SK, Harrison C, Stepto N et al.. “Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.” Diabetes care (2008). PMID: 18390799 ↗

    L4RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  127. [127]

    Kumarendran B, O'Reilly MW, Subramanian A et al.. “Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study.” Diabetes care (2021). PMID: 34649997 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  128. [128]

    Hirschberg AL. “Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36409990 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  129. [129]

    Joham AE, Tay CT, Laven J et al.. “Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39836632 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  130. [130]

    Gibson-Helm M, Teede H, Dunaif A et al.. “Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27906550 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  131. [131]

    Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE et al.. “Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.” Diabetes care (2006). PMID: 16443877 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  132. [132]

    Glintborg D, Andersen M. “MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome.” European journal of endocrinology (2016). PMID: 27601016 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
  133. [133]

    Subramanian A, Anand A, Adderley NJ et al.. “Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study.” European journal of endocrinology (2021). PMID: 33635829 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  134. [134]

    Vrbikova J, Hill M, Bendlova B et al.. “Incretin levels in polycystic ovary syndrome.” European journal of endocrinology (2008). PMID: 18511472 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  135. [135]

    Sathyapalan T, Atkin SL. “Recent advances in cardiovascular aspects of polycystic ovary syndrome.” European journal of endocrinology (2011). PMID: 22096112 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  136. [136]

    Möhlig M, Flöter A, Spranger J et al.. “Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.” Diabetologia (2006). PMID: 16972044 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  137. [137]

    Guo X, Cui J, Jones MR et al.. “Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis.” Diabetologia (2012). PMID: 22584727 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  138. [138]

    Huang P, Li Y, Kong FS et al.. “A Risk Score for Polycystic Ovary Syndrome Based on Meta-Analysis and Machine Learning of Gut Microbiota Signatures.” Reproductive sciences (Thousand Oaks, Calif.) (2026). PMID: 42321548 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  139. [139]

    Yu H, Peng L. “Artificial intelligence in ovarian pathophysiology and management: a systematic review and meta-analysis.” Journal of ovarian research (2026). PMID: 42092958 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
  140. [140]

    Liu T, Bo W, Cao Q et al.. “The accuracy of lipid accumulation product to predict metabolic syndrome in PCOS: a meta-analysis and comparative analysis with other indicators.” Frontiers in endocrinology (2026). PMID: 42064769 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  141. [141]

    Rosenfield RL. “Normal and Premature Adrenarche.” Endocrine reviews (2021). PMID: 33788946 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  142. [142]

    Patel B, Koysombat K, Mills EG et al.. “The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.” Endocrine reviews (2024). PMID: 37467734 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
  143. [143]

    Showell MG, Mackenzie-Proctor R, Jordan V et al.. “Inositol for subfertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2018). PMID: 30570133 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
  144. [144]

    Zhang B, Mitsunami M, Peebles E et al.. “Early-life exposure to ambient temperature and polycystic ovary syndrome: a nationwide cohort study.” International journal of epidemiology (2026). PMID: 42204813 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  145. [145]

    Patrick H, McAlister L, Pourtousi A et al.. “Opportunities to improve the care of individuals with polycystic ovary syndrome in Canada: Systematic review.” Canadian family physician Medecin de famille canadien (2026). PMID: 41980840 ↗

    L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  146. [146]

    Shan D, Han J, Cai Y et al.. “Reproductive Health in First-degree Relatives of Patients With Polycystic Ovary Syndrome: A Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34453540 ↗

    L2SR_OBSCited in: Severity, Staging and Risk Stratification
  147. [147]

    Jéru I, Vantyghem MC, Bismuth E et al.. “Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31504636 ↗

    L4CASE_REPORTCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
  148. [148]

    Pasquali R, Gambineri A. “Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 24272197 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
  149. [149]

    Rosenfield RL. “The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015.” Endocrine reviews (2024). PMID: 38457123 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
  150. [150]

    Xiong T, Fraison E, Kolibianaki E et al.. “Statins for women with polycystic ovary syndrome not actively trying to conceive.” The Cochrane database of systematic reviews (2023). PMID: 37462232 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  151. [151]

    Aytemiz EA, Aslan B, Kaplan NB et al.. “Phenotype-specific efficacy of letrozole versus clomiphene citrate in polycystic ovary syndrome: a prospective cohort study.” BMC women's health (2026). PMID: 41826916 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  152. [152]

    Bashir R, Asrar M, Kamboj S et al.. “Metabolic-endocrine correlates of gut-brain axis mediators in polycystic ovary syndrome: A case-control study.” Journal of neuroendocrinology (2026). PMID: 42076786 ↗

    L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification
  153. [153]

    Buragohain S, Sarma I, Saikia D et al.. “Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Cureus (2026). PMID: 42116999 ↗

    L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification
  154. [154]

    Parker MN, Richards CA, Brydum R et al.. “Psychiatric Diagnoses and Psychotropic Medications Among Military-Affiliated Adolescents and Young Adults With Polycystic Ovary Syndrome.” The Journal of adolescent health : official publication of the Society for Adolescent Medicine (2026). PMID: 42429714 ↗

    L3OTHERCited in: Severity, Staging and Risk Stratification
  155. [155]

    Ropelato MG, Rudaz MC, Escobar ME et al.. “Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19567528 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  156. [156]

    Pau CT, Keefe C, Duran J et al.. “Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24606093 ↗

    L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
  157. [157]

    Costa S, Sampaio L, Berta Sousa A et al.. “Face-sparing Congenital Generalized Lipodystrophy Type 1 Associated With Nonclassical Congenital Adrenal Hyperplasia.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35857714 ↗

    L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
  158. [158]

    Dumesic DA, Phan JD, Leung KL et al.. “Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30649347 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies
  159. [159]

    O'Reilly MW, Kempegowda P, Walsh M et al.. “AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28645211 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  160. [160]

    Benrick A, Pillon NJ, Nilsson E et al.. “Electroacupuncture Mimics Exercise-Induced Changes in Skeletal Muscle Gene Expression in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32232327 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  161. [161]

    Maliqueo M, Sir-Petermann T, Pérez V et al.. “Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19567527 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  162. [162]

    Insenser M, Martínez-García MA, Montes R et al.. “Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20484478 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  163. [163]

    Tosi F, Di Sarra D, Bonin C et al.. “Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome.” European journal of endocrinology (2014). PMID: 24347428 ↗

    L3OTHERCited in: Acute Management and Endocrine Emergencies
  164. [164]

    Berbrier DE, Huckins W, Delage SI et al.. “Ketone monoester ingestion improves endothelial function during hyperglycemia in females with polycystic ovary syndrome.” American journal of physiology. Endocrinology and metabolism (2026). PMID: 41494652 ↗

    L4RCTCited in: Acute Management and Endocrine Emergencies
  165. [165]

    Rajab E, Moin ASM, Nandakumar M et al.. “Shared and divergent acute cardiovascular risk protein responses to lipid infusion in women with and without PCOS.” Diabetes, obesity & metabolism (2025). PMID: 41017577 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  166. [166]

    Chen L, Lu J, Hu J et al.. “Unveiling the multifaceted role of adropin in various diseases (Review).” International journal of molecular medicine (2024). PMID: 39155866 ↗

    L5SR_OBSCited in: Acute Management and Endocrine Emergencies
  167. [167]

    Holmskov M, Christensen J, Larsen MF et al.. “Polycystic ovary syndrome in women with bipolar affective disorder or epilepsy exposed to valproic acid: a nationwide 16-year cohort study.” International journal of bipolar disorders (2026). PMID: 41533184 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies
  168. [168]

    Gastaldon C, Whitesell Skrivankova V, Schoretsanitis G et al.. “Diagnosis of postpartum depression and associated factors in South Africa: a cohort study of 47,697 women.” Epidemiology and psychiatric sciences (2025). PMID: 40726088 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies
  169. [169]

    Verfürden ML, Schnecke V, Winning Lehmann E et al.. “Association between weight loss and reproductive outcomes among women with overweight or obesity: a cohort study using UK real-world data.” Human reproduction (Oxford, England) (2025). PMID: 40618200 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies
  170. [170]

    Yu EH, Lee HJ, Joo JK et al.. “Comparing programmed, modified natural and natural cycle frozen embryo transfer on obstetric outcomes in polycystic ovary syndrome: a national cohort study.” Journal of assisted reproduction and genetics (2025). PMID: 40531303 ↗

    L2COHORTCited in: Acute Management and Endocrine Emergencies
  171. [171]

    Guo X, Yao Y, Wang T et al.. “The impact of hyperandrogenemia on pregnancy complications and outcomes in patients with PCOS: a systematic review and meta-analysis.” Hypertension in pregnancy (2024). PMID: 39004840 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies
  172. [172]

    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI et al.. “Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.” Diabetes care (2007). PMID: 17536071 ↗

    L4RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  173. [173]

    Yang M, Liu R, Li S et al.. “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.” Diabetes care (2012). PMID: 23275352 ↗

    L4RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  174. [174]

    Glintborg D, Højlund K, Andersen M et al.. “Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.” Diabetes care (2007). PMID: 18000176 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  175. [175]

    Salamun V, Jensterle M, Janez A et al.. “Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.” European journal of endocrinology (2018). PMID: 29703793 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  176. [176]

    Rittig N, Christiansen Arlien-Søborg M, Svart MV et al.. “Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial.” European journal of endocrinology (2025). PMID: 40393075 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  177. [177]

    Shang Y, Zhou H, Hu M et al.. “Effect of Diet on Insulin Resistance in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32621748 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  178. [178]

    Melin J, Forslund M, Alesi S et al.. “Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37554096 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  179. [179]

    Chen ZJ, Shi Y, Sun Y et al.. “Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome.” The New England journal of medicine (2016). PMID: 27509101 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  180. [180]

    Shi Y, Sun Y, Hao C et al.. “Transfer of Fresh versus Frozen Embryos in Ovulatory Women.” The New England journal of medicine (2018). PMID: 29320646 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  181. [181]

    Legro RS, Barnhart HX, Schlaff WD et al.. “Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.” The New England journal of medicine (2007). PMID: 17287476 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  182. [182]

    Vuong LN, Dang VQ, Ho TM et al.. “IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.” The New England journal of medicine (2018). PMID: 29320655 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  183. [183]

    Kjerpeseth LJ, Cesta CE, Furu K et al.. “Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study.” Diabetes care (2023). PMID: 37343541 ↗

    L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  184. [184]

    Forslund M, Melin J, Alesi S et al.. “Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis.” European journal of endocrinology (2023). PMID: 37440702 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  185. [185]

    Smedegaard S, Rittig N, Ovesen PG et al.. “Once-daily supplementation with pre-meal whey protein lowers breakfast postprandial glucose levels in women with GDM throughout the third trimester: a randomised, controlled, clinical trial.” Diabetologia (2025). PMID: 41203981 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  186. [186]

    Palomba S, Falbo A, Giallauria F et al.. “Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome.” Diabetes care (2009). PMID: 19933994 ↗

    L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  187. [187]

    Pasquali R, Gambineri A. “Insulin-sensitizing agents in polycystic ovary syndrome.” European journal of endocrinology (2006). PMID: 16728533 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
  188. [188]

    Bult MJ, van Dalen T, Muller AF. “Surgical treatment of obesity.” European journal of endocrinology (2008). PMID: 18230819 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  189. [189]

    Aminian M, Hajshafiha M, Heidari M et al.. “Effect of two types of time-restricted eating on glycemic, lipid indices, and weight in women with polycystic ovary syndrome: a randomized controlled trial.” European journal of nutrition (2026). PMID: 42371138 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  190. [190]

    Mu L, Shen Y, Wang G et al.. “Dihydroartemisinin for the treatment of polycystic ovary syndrome: study protocol for a multi-centre placebo-controlled randomised clinical trial.” BMJ open (2026). PMID: 42320967 ↗

    L5TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  191. [191]

    Sharifi M, Dehghani MJ, Karimi MA et al.. “Serum anti-Müllerian hormone levels in women following bariatric surgery: insights from a systematic review and meta-analysis.” BMC endocrine disorders (2026). PMID: 42401855 ↗

    L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  192. [192]

    Gautam R, Maan P, Arora A et al.. “Yoga as a complementary intervention for polycystic ovary Syndrome management: a systematic review.” Frontiers in reproductive health (2026). PMID: 42318079 ↗

    L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  193. [193]

    Chen Y, Wang G, Chen J et al.. “Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome.” Endocrine reviews (2024). PMID: 38298137 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  194. [194]

    Mueller JW, Gilligan LC, Idkowiak J et al.. “The Regulation of Steroid Action by Sulfation and Desulfation.” Endocrine reviews (2015). PMID: 26213785 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  195. [195]

    Palomba S, Falbo A, Zullo F et al.. “Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.” Endocrine reviews (2008). PMID: 19056992 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  196. [196]

    Morley LC, Tang T, Yasmin E et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2017). PMID: 29183107 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  197. [197]

    Shawish MI, Bagheri B, Musini VM et al.. “Effect of atorvastatin on testosterone levels.” The Cochrane database of systematic reviews (2021). PMID: 33482034 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  198. [198]

    Xie M, Zhou S, Wu J et al.. “Determinants of dropout from lifestyle interventions for overweight polycystic ovary syndrome: An exploratory analysis of randomized controlled trial.” PloS one (2026). PMID: 42361044 ↗

    L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  199. [199]

    Wang J, Zhou W, Song Z et al.. “Does the Risk of Embryo Abnormality Increase in PCOS Women? A Secondary Analysis of a Multicenter, Randomized Controlled Trial.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36546342 ↗

    L2RCTCited in: History and Evolution of Treatment
  200. [200]

    Marchesan LB, da Silva TR, Spritzer PM. “Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39271474 ↗

    L1RCTCited in: History and Evolution of Treatment
  201. [201]

    Mantzoros CS, Dunaif A, Flier JS. “Leptin concentrations in the polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (1997). PMID: 9177364 ↗

    L3RCTCited in: History and Evolution of Treatment
  202. [202]

    Belan M, Giguère-Johnson M, Carranza-Mamane B et al.. “Lifestyle intervention before and during fertility treatment in women with obesity or with overweight and PCOS-a RCT.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41402995 ↗

    L1RCTCited in: History and Evolution of Treatment
  203. [203]

    Fraser GL, Obermayer-Pietsch B, Laven J et al.. “Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34000049 ↗

    L1RCTCited in: History and Evolution of Treatment
  204. [204]

    McDonnell T, Anthony AV, Clarke G et al.. “Hepatic metabolism of 11-oxygenated androgens in humans: an integrated in vivo and ex vivo approach.” European journal of endocrinology (2025). PMID: 40795393 ↗

    L4RCTCited in: History and Evolution of Treatment
  205. [205]

    Kelly CJ, Gordon D. “The effect of metformin on hirsutism in polycystic ovary syndrome.” European journal of endocrinology (2002). PMID: 12153743 ↗

    L1RCTCited in: History and Evolution of Treatment
  206. [206]

    Gashaw I, Reif S, Wiesinger H et al.. “Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.” European journal of endocrinology (2023). PMID: 37306288 ↗

    L4RCTCited in: History and Evolution of Treatment
  207. [207]

    Donà G, Sabbadin C, Fiore C et al.. “Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.” European journal of endocrinology (2012). PMID: 22223702 ↗

    L1RCTCited in: History and Evolution of Treatment
  208. [208]

    Oberg E, Lundell C, Blomberg L et al.. “Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial.” European journal of endocrinology (2020). PMID: 32503005 ↗

    L1RCTCited in: History and Evolution of Treatment
  209. [209]

    Nestler JE, Jakubowicz DJ, Reamer P et al.. “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.” The New England journal of medicine (1999). PMID: 10219066 ↗

    L1RCTCited in: History and Evolution of Treatment
  210. [210]

    Nestler JE, Jakubowicz DJ. “Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.” The New England journal of medicine (1996). PMID: 8687515 ↗

    L4RCTCited in: History and Evolution of Treatment
  211. [211]

    Dennedy MC, Smith D, O'Shea D et al.. “Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma.” European journal of endocrinology (2009). PMID: 19906851 ↗

    L5CASE_REPORTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
  212. [212]

    Xita N, Tsatsoulis A. “Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16522691 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  213. [213]

    Ramachandran A, Snehalatha C, Satyavani K et al.. “Type 2 diabetes in Asian-Indian urban children.” Diabetes care (2003). PMID: 12663567 ↗

    L4OTHERCited in: History and Evolution of Treatment
  214. [214]

    Ehrmann DA, Barnes RB, Rosenfield RL et al.. “Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.” Diabetes care (1999). PMID: 10333916 ↗

    L4OTHERCited in: History and Evolution of Treatment
  215. [215]

    Farquhar C, Lilford RJ, Marjoribanks J et al.. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2005). PMID: 16034856 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  216. [216]

    Farquhar C, Vandekerckhove P, Lilford R. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2001). PMID: 11687100 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  217. [217]

    Farquhar C, Lilford RJ, Marjoribanks J et al.. “Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2007). PMID: 17636653 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  218. [218]

    Farquhar C, Vandekerckhove P, Arnot M et al.. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2000). PMID: 10796746 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  219. [219]

    Farquhar C, Brown J, Marjoribanks J. “Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2012). PMID: 22696324 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  220. [220]

    Hughes E, Collins J, Vandekerckhove P. “WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.” The Cochrane database of systematic reviews (1996). PMID: 17636586 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  221. [221]

    Nugent D, Vanderkerchove P, Hughes E et al.. “WITHDRAWN: Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2015). PMID: 26299777 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  222. [222]

    Nahuis M, Bayram N, Van der Veen F et al.. “WITHDRAWN: Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2015). PMID: 26299778 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  223. [223]

    Yang Z, Xu Y, Du H et al.. “Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.” Diabetes, obesity & metabolism (2026). PMID: 42236268 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  224. [224]

    Ren J, Chen H, Zhang L et al.. “Effects of Tai Chi combined with dietary intervention on health-promoting lifestyle and metabolic and reproductive outcomes in female college students with polycystic ovary syndrome: a randomized controlled trial.” Frontiers in endocrinology (2026). PMID: 42147112 ↗

    L1RCTCited in: History and Evolution of Treatment
  225. [225]

    Corapi S, Runchey MC, Lyons J et al.. “Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial.” Nature medicine (2026). PMID: 41896647 ↗

    L1RCTCited in: History and Evolution of Treatment
  226. [226]

    Samarasinghe SNS, Abbara A, Ortega PM et al.. “Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial.” Human reproduction (Oxford, England) (2026). PMID: 41808368 ↗

    L2RCTCited in: History and Evolution of Treatment
  227. [227]

    Hosseinabad MF, Masnavi E, Eslamnik PA et al.. “Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study.” Journal of gynecology obstetrics and human reproduction (2026). PMID: 41881108 ↗

    L1RCTCited in: History and Evolution of Treatment
  228. [228]

    Behroozilak T, Farshadfar M, Jahangard S. “Effect of Probiotic Supplementation on Reproductive Outcomes of Women With Polycystic Ovary Syndrome Who Are Candidates for Intrauterine Insemination: A Randomized, Double-Blind, Placebo-Controlled Trial.” Endocrinology, diabetes & metabolism (2026). PMID: 41776814 ↗

    L1RCTCited in: History and Evolution of Treatment
  229. [229]

    Taheri H, Seydi F, Jalali-Mashayekhi F et al.. “Effects of Arctium lappa L. Root Powder on Some Markers of Oxidative Stress and Inflammation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clinical Trial Study.” JBRA assisted reproduction (2026). PMID: 41757842 ↗

    L1RCTCited in: History and Evolution of Treatment
  230. [230]

    Liu Y, Yu H, Peng J et al.. “Construction and validation of a machine learning model for predicting early pregnancy in patients with polycystic ovary syndrome: a retrospective cohort study.” Journal of ovarian research (2026). PMID: 42415121 ↗

    L2COHORTCited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  231. [231]

    Shao C, Li W, Liang J. “Effects of acupuncture on improving hormonal and metabolic biochemical characteristics in polycystic ovary syndrome.” African journal of reproductive health (2026). PMID: 41841598 ↗

    L1RCTCited in: History and Evolution of Treatment
  232. [232]

    Melin J, Forslund M, Alesi S et al.. “The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.” European journal of endocrinology (2023). PMID: 37536294 ↗

    L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  233. [233]

    Fitz V, Graca S, Mahalingaiah S et al.. “Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38163998 ↗

    L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  234. [234]

    Hutchison SK, Teede HJ, Rachoń D et al.. “Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome.” Diabetologia (2012). PMID: 22246378 ↗

    L2RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  235. [235]

    Wojciechowski P, Lipowska A, Rys P et al.. “Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis.” Diabetologia (2012). PMID: 22801903 ↗

    L3SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  236. [236]

    Sun Z, Zhang R, Tian X et al.. “Efficacy of probiotic and synbiotic supplementation on metabolic and endocrine parameters in polycystic ovary syndrome: a meta-analysis of randomized controlled trials.” BMC endocrine disorders (2026). PMID: 42420973 ↗

    L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  237. [237]

    Liu Q, Tang B, Zhu Z et al.. “A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome.” Diabetologia (2022). PMID: 35771237 ↗

    L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  238. [238]

    Moreira MV, Guerra-Carvalho B, Vale-Fernandes E et al.. “Metabolic profiling of human follicular fluid to unravel the pathways involved in polycystic ovary syndrome - a systematic review.” Reviews in endocrine & metabolic disorders (2026). PMID: 42406284 ↗

    L3SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  239. [239]

    Rajendran R, Abdul Khader M, Shivanna P et al.. “Screening for endometrial hyperplasia and endometrial cancer in premenopausal women with polycystic ovary syndrome: a systematic review protocol.” BMJ open (2026). PMID: 42379723 ↗

    L5SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  240. [240]

    Rosenfield RL, Ehrmann DA. “The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.” Endocrine reviews (2016). PMID: 27459230 ↗

    L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  241. [241]

    Riestenberg C, Jagasia A, Markovic D et al.. “Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34546364 ↗

    L2SR_OBSCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  242. [242]

    Domecq JP, Prutsky G, Mullan RJ et al.. “Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24092830 ↗

    L2SR_OBSCited in: Complications and Long-term Sequelae
  243. [243]

    Glintborg D, Ollila MM, Koskenkari N et al.. “Increased prospective cardiovascular disease risk in 127 517 Nordic women with polycystic ovary syndrome: a national cohort study.” European journal of endocrinology (2026). PMID: 41439462 ↗

    L2COHORTCited in: Complications and Long-term Sequelae
  244. [244]

    Wang ET, Cirillo PM, Vittinghoff E et al.. “Menstrual irregularity and cardiovascular mortality.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20980429 ↗

    L2OTHERCited in: Complications and Long-term Sequelae
  245. [245]

    Macut D, Božić-Antić I, Bjekić-Macut J et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.” European journal of endocrinology (2017). PMID: 28694246 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  246. [246]

    Sharpe A, Morley LC, Tang T et al.. “Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 31845767 ↗

    L1SR_OBSCited in: Complications and Long-term Sequelae
  247. [247]

    Bordewijk EM, Ng KYB, Rakic L et al.. “Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 32048270 ↗

    L1SR_OBSCited in: Complications and Long-term Sequelae
  248. [248]

    Wang F, Fu L, Zhou T et al.. “Gestational lipid profile partially mediates adverse obstetric outcomes associated with polycystic ovary syndrome: a multicentre cohort study in China.” Lipids in health and disease (2026). PMID: 42402586 ↗

    L3COHORTCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  249. [249]

    Tang M, Deng X, Liu S et al.. “Polyendocrine metabolic ovarian syndrome and cardiometabolic profile in offspring: a propensity score matched cohort study.” Reproductive biomedicine online (2026). PMID: 42364288 ↗

    L3COHORTCited in: Complications and Long-term Sequelae
  250. [250]

    Varma R, Ilelaboye A, Ugwuja F et al.. “Hormonal therapy and cardiovascular risk in polycystic ovary syndrome: a propensity-matched cohort study.” Proceedings (Baylor University. Medical Center) (2026). PMID: 42269075 ↗

    L3COHORTCited in: Complications and Long-term Sequelae
  251. [251]

    Salley KE, Wickham EP, Cheang KI et al.. “Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.” The Journal of clinical endocrinology and metabolism (2007). PMID: 18056778 ↗

    L5SR_OBSCited in: Prognosis, Natural History and Prevention
  252. [252]

    Domecq JP, Prutsky G, Mullan RJ et al.. “Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24092832 ↗

    L1SR_OBSCited in: Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  253. [253]

    van der Ham K, Moolhuijsen LME, Brewer K et al.. “Clustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38753423 ↗

    L4OTHERCited in: Prognosis, Natural History and Prevention
  254. [254]

    Dunaif A, Fauser BC. “Renaming PCOS--a two-state solution.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24009134 ↗

    L5OTHERCited in: Prognosis, Natural History and Prevention
  255. [255]

    Rosenfield RL. “Clinical review: Identifying children at risk for polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2006). PMID: 17179197 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  256. [256]

    Pasquali R, Diamanti-Kandarakis E, Gambineri A. “MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects.” European journal of endocrinology (2016). PMID: 27170519 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  257. [257]

    Lecot-Connan T, Bachelot G, Donadille B et al.. “Using machine learning to discriminate non-classical 21-hydroxylase deficiency from polycystic ovary syndrome: an external validation study.” European journal of endocrinology (2026). PMID: 42411601 ↗

    L4OTHERCited in: Prognosis, Natural History and Prevention
  258. [258]

    Luque-Ramírez M, Alpañés M, Sanchón R et al.. “Referral bias in female functional hyperandrogenism and polycystic ovary syndrome.” European journal of endocrinology (2015). PMID: 26243032 ↗

    L4OTHERCited in: Prognosis, Natural History and Prevention
  259. [259]

    Muscogiuri G, Mitri J, Mathieu C et al.. “Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease.” European journal of endocrinology (2014). PMID: 24872497 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  260. [260]

    Livadas S, Yildiz BO, Mastorakos G et al.. “European survey of diagnosis and management of the polycystic ovary syndrome: full report on the ESE PCOS Special Interest Group's 2023 Questionnaire.” European journal of endocrinology (2024). PMID: 39099229 ↗

    L4OTHERCited in: Prognosis, Natural History and Prevention
  261. [261]

    Gui Z, Lin H, Wang C et al.. “Association between bisphenol exposure and polycystic ovary syndrome risk: an integrated systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42369063 ↗

    L3SR_OBSCited in: Prognosis, Natural History and Prevention
  262. [262]

    Hu S, Shen Q, Li Z et al.. “Ranking exercise interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis.” Reproductive biology and endocrinology : RB&E (2026). PMID: 42050523 ↗

    L1SR_OBSCited in: Prognosis, Natural History and Prevention
  263. [263]

    Youssef MA, Mourad S. “Volume expanders for the prevention of ovarian hyperstimulation syndrome.” The Cochrane database of systematic reviews (2016). PMID: 27577848 ↗

    L1SR_OBSCited in: Prognosis, Natural History and Prevention
  264. [264]

    Helseth R, Vanky E, Salvesen O et al.. “Gestational diabetes mellitus among Norwegian women with polycystic ovary syndrome: prevalence and risk factors according to the WHO and the modified IADPSG criteria.” European journal of endocrinology (2013). PMID: 23636445 ↗

    L2RCTCited in: Special Populations, Pregnancy and Fertility
  265. [265]

    Ott J, Wattar L, Kurz C et al.. “Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study.” European journal of endocrinology (2012). PMID: 22330149 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility
  266. [266]

    Palomba S. “Aromatase inhibitors for ovulation induction.” The Journal of clinical endocrinology and metabolism (2015). PMID: 25710566 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
  267. [267]

    Paalanne M, Vääräsmäki M, Mustaniemi S et al.. “Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm.” European journal of endocrinology (2021). PMID: 34081616 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  268. [268]

    Vryonidou A, Paschou SA, Muscogiuri G et al.. “MECHANISMS IN ENDOCRINOLOGY: Metabolic syndrome through the female life cycle.” European journal of endocrinology (2015). PMID: 26034072 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
  269. [269]

    Shi Z, Li F, Gao T et al.. “Investigation of trends, hot spots and effective therapies for pregnancy outcomes in polycystic ovary syndrome: a bibliometric analysis.” Frontiers in medicine (2026). PMID: 42221129 ↗

    L5SR_OBSCited in: Special Populations, Pregnancy and Fertility
  270. [270]

    Clark KL, George JW, Przygrodzka E et al.. “Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease.” Endocrine reviews (2022). PMID: 35596657 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
  271. [271]

    Xu H, Li J, Yin SQ et al.. “Impact of concordance between basal LH/FSH ratio and testosterone levels on pregnancy outcomes in patients with PCOS undergoing IVF-ET cycle: a retrospective cohort study.” Journal of endocrinological investigation (2026). PMID: 42287529 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility

Revision History

All updates applied to this page

Loading revisions…